• Use for infant drug testing when only benzodiazepine exposure is of clinical interest or when quantity of meconium available for testing is very small (eg, <1 g).
• Preferred test is Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation (0092516)
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears.
Transport 1 g (equivalent to 1/2 inch cube) for each separate confirmation required. (Min: 0.5 g or 1/4 inch cube)
Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Drugs covered: alprazolam, alpha-hydroxyalprazolam, clonazepam, 7-aminoclonazepam, diazepam, chlordiazepoxide, lorazepam, midazolam, alpha-hydroxymidazolam, nordiazepam, oxazepam, and temazepam.
Positive cutoff: 20 ng/g unless specified below:
Alprazolam 5 ng/g
Alpha-hydroxyalprazolam 5 ng/g
Diazepam 5 ng/g
Clonazepam 5 ng/g
7-aminoclonazepam 5 ng/g
Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by mother. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Laboratory Developed Test (LDT)
80346 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
|0092520||Drug Confirmation, Benzodiazepine, Mec||29160-9|
- Mono Demetrin